2-Decarboxy-2-tetrazolyl-4-halo-5,9-epoxy-9-deoxy-PGF1 compounds

ABSTRACT

The present invention relates to novel 2-decarboxy-2-tetrazolyl-4-halo-5,9-epoxy-9-deoxy-PGF 1  compounds, which are intermediates useful for the preparation of corresponding 5,9α-epoxy-9-deoxy-PGF 1  and 5,9-epoxy-9-deoxy-4,5-didehydro-PGF 1  compounds. These end products are employed for induction of a variety of prostacyclinlike pharmacological effects. Accordingly, these end products are useful pharmacological agents for the same purposes for which prostacyclin is employed.

CROSS REFERENCE TO RELATED APPLICATION

The present application is a divisional application of United Stated Ser. No. 932,981, filed Aug. 11, 1978, now pending issuance as a United States patent; which is a divisional application of United States Ser. No. 819,856, filed July 28, 1977, now United States Patent 4,123,441; which is a continuation-in-part application of United States Ser. No. 725,546, filed Sept. 22, 1976, now abandoned; which is a continuation-in-part application of United States Ser. No. 716,960, filed Aug. 23, 1976, now abandoned.

BACKGROUND OF THE INVENTION

The present invention relates to novel 2-decarboxy-2-tetrazolyl-4-halo-5,9-epoxy-9-deoxy-PGF₁ compounds, which are intermediates useful for the preparation of corresponding 5,9α-epoxy-9-deoxy-PGF₁ and 5,9-epoxy-9-deoxy-4,5-didehydro-PGF₁ compounds. These end products are employed for induction of a variety of prostacyclin-like pharmacological effects. Accordingly, these end products are useful pharmacological agents for the same purposes for which prostacyclin is employed.

The essential material constituting a disclosure of the preparation and use of the novel compounds of the present invention is incorporated here by reference from United States Pat. No. 4,123,441.

SUMMARY OF THE INVENTION

The present invention particularly provides:

a compound of the formula ##STR1## wherein W₁ is α-OH:β-H, α-H:β-OH, oxo, methylene, α-H:β-H, α-CH₂ OH:β-H;

wherein L is

(1) --(CH₂)_(d) --C(R₂)₂,

(2) --O--CH₂ --Y, or

(3) --CH═CH--,

wherein d is zero to 5, R₂ is hydrogen, methyl, or fluoro, being the same or different with the proviso that one R₂ is not methyl when the other is fluoro, and Y is a valence bond, --CH₂ -- or --(CH₂)₂ --,

wherein Q is oxo, α-H:β-H, α-OH:β-R₈ or α-R₈ :β-OH

wherein R₈ is hydrogen or alkyl of one to 4 carbon atoms, inclusive,

wherein R₄ is

(1) --CR₅ R₆ --C_(g) H_(2g) ═CH₃

(2) --CR₅ R₆ --Z--(Ph)

(3) cis--CH₂ --CH═CH--CH₂ CH₃

wherein C_(g) H_(2g) is alkylene of one to 9 carbon atoms, inclusive, with one to 5 carbon atoms, inclusive, in the chain between --CR₅ R₆ -- and terminal methyl, wherein R₅ and R₆ are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R₅ and R₆ is fluoro only when the other is hydrogen or fluoro and the further proviso that neither R₅ nor R₆ is fluoro when Z is oxa (--O--); wherein Z represents an oxa atom (--O--) or C_(j) H_(2j) wherein C_(j) H_(2j) is a valence bond or alkylene of one to 9 carbon atoms, inclusive, with one to 6 carbon atoms, inclusive between CR₅ R₆ -- and the (Ph); wherein (Ph) is phenyl or phenyl substituted by (T)s, wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR₇ --, wherein R₇ is alkyl of one to 4 carbon atoms, inclusive, and s is zero, one, 2, or 3, with the proviso that not more than two T's are other than alkyl and when s is 2 or 3 the T's are either the same or different;

wherein R₁₉ is chloro, bromo, or iodo; and

wherein X is

(1) trans--CH═CH--

(2) cis--CH═CH--

(3) --C.tbd.C-- or

(4) --CH₂ CH₂ --.

With regard to the divalent substituents described in the claims, e.g., Q and W₁, these divalent radicals are defined as α-R_(i) :β-R_(j), where R_(i) represents a substituent of the divalent moiety of the alpha configuration with respect to the cyclopentane and R_(j) represents a substituent of the divalent moiety of the beta configuration with respect to the cyclopentane ring. Accordingly, when Q is defined as α-OH:β-R₈, the hydroxy of the Q moiety is in the alpha configuration, i.e., as in prostacyclin, and the R₈ substituent is in the beta configuration. Not all carbon atoms to which such divalent moieties are attached represent asymmetric centers. For example, when both valence bonds are to hydrogen (e.g., W₁ or Q is α-H:β-H), then no asymmetric center is present.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention particularly relates to the following chemical compounds:

2-Decarboxy-2-tetrazolyl-4ξ-iodo-9-deoxy-5ξ,9α-epoxy-PGF₁ ;

2-Decarboxy-2-tetrazolyl-4ξ-bromo-9-deoxy-5ξ,9α-epoxy-PGF₁ ;

2-Decarboxy-2-tetrazolyl-4ξ-iodo-9-deoxy-5ξ,9α-epoxy-15-keto-PGF₁ ;

2-Decarboxy-2-tetrazolyl-4ξ-iodo-9-deoxy-5ξ,9α-epoxy-15-deoxy-PGF₁ ; and

2-Decarboxy-2-tetrazolyl-4ξ-iodo-9-deoxy-5ξ,9α-epoxy-17-phenyl-18,19,20-trinor-PGF₁ ; 

I claim:
 1. A compound of the formula ##STR2## wherein W₁ is α-OH:β-H, α-H:β-OH, oxo, methylene, α-H:β-H, α-CH₂ OH:β-H;wherein L is (1) --(CH₂)_(d) --C(R₂)₂, (2) --O--CH₂ --Y, or (3) --CH═CH--,wherein d is zero to 5, R₂ is hydrogen, methyl, or fluoro, being the same or different with the proviso that one R₂ is not methyl when the other is fluoro, and Y is a valence bond, --CH₂ -- or --(CH₂)₂ --, wherein Q is oxo, α-H:β-H, α-OH:β-R₈ or α-R₈ :β-OHwherein R₈ is hydrogen or alkyl of one to 4 carbon atoms, inclusive, wherein R₄ is (1) --CR₅ R₆ --C_(g) H_(2g) ═CH₃ (2) --CR₅ R₆ --Z--(Ph) (3) cis--CH₂ --CH═CH--CH₂ CH₃ wherein C_(g) H_(2g) is alkylene of one to 9 carbon atoms, inclusive, with one to 5 carbon atoms, inclusive, in the chain between --CR₅ R₆ -- and terminal methyl, wherein R₅ and R₆ are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R₅ and R₆ is fluoro only when the other is hydrogen or fluoro and the further proviso that neither R₅ nor R₆ is fluoro when Z is oxa (--O--); wherein Z represents an oxa atom (--O--) or C_(j) H_(2j) wherein C_(j) H_(2j) is a valence bond or alkylene of one to 9 carbon atoms, inclusive, with one to 6 carbon atoms, inclusive between CR₅ R₆ -- and the (Ph); wherein (Ph) is phenyl or phenyl substituted by (T)s, wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR₇ --, wherein R₇ is alkyl of one to 4 carbon atoms, inclusive, and s is zero, one, 2, or 3, with the proviso that not more than two T's are other than alkyl and when s is 2 or 3 the T's are either the same or different; wherein R₁₉ is chloro, bromo, or iodo; and wherein X is (1) trans--CH═CH-- (2) cis--CH═CH-- (3) --C.tbd.C-- or (4) --CH₂ CH₂ --.
 2. A compound according to claim 1, wherein W is α-OH:β-H.
 3. A compound according to claim 2, wherein L is --(CH₂)_(n) --, n being 2, 3, or 4, wherein Q is oxo or α-OH:β-R₈ and wherein R₈ is hydrogen, methyl, or ethyl, and wherein R₄ is n-pentyl, 1,1-dimethylpentyl, 1,1-difluoropentyl, phenoxymethyl or phenylethyl.
 4. A compound according to claim 3, wherein X is trans--CH═CH--.
 5. 2-Decarboxy-2-tetrazolyl-4ξ-iodo-9-deoxy-5ξ,9α-epoxy-PGF₁, a compound according to claim
 4. 6. 2-Decarboxy-2-tetrazolyl-4ξ-bromo-9-deoxy-5ξ,9α-epoxy-PGF₁, a compound according to claim
 4. 7. 2-Decarboxy-2-tetrazolyl-4ξ-iodo-9-deoxy-5ξ,9α-epoxy-15-keto-PGF₁, a compound according to claim
 4. 8. 2-Decarboxy-2-tetrazolyl-4ξ-iodo-9-deoxy-5.xi.,9α-epoxy-15-deoxy-PGF₁, a compound according to claim
 4. 9. 2-Decarboxy-2-tetrazolyl-4ξ-iodo-9-deoxy-5ξ,9α-epoxy-17-phenyl-18,19,20-trinor-PGF₁, a compound according to claim
 4. 